CL2017001680A1 - Pharmaceutical composition for the treatment of gastrointestinal diseases - Google Patents

Pharmaceutical composition for the treatment of gastrointestinal diseases

Info

Publication number
CL2017001680A1
CL2017001680A1 CL2017001680A CL2017001680A CL2017001680A1 CL 2017001680 A1 CL2017001680 A1 CL 2017001680A1 CL 2017001680 A CL2017001680 A CL 2017001680A CL 2017001680 A CL2017001680 A CL 2017001680A CL 2017001680 A1 CL2017001680 A1 CL 2017001680A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
sucralphate
subcitrate
Prior art date
Application number
CL2017001680A
Other languages
Spanish (es)
Inventor
Jun Woo Lee
Young Ho Jo
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of CL2017001680A1 publication Critical patent/CL2017001680A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE ENFERMEDADES GASTROINTESTINALES QUE COMPRENDE RANITIDINA, SUCRALFATO Y SUBCITRATO DE BISMUTO COMO COMPONENTES ACTIVOS Y UN MÉTODO DE PREPARACIÓN DE LOS MISMOS. DE ACUERDO CON LA PRESENTE INVENCIÓN, CUANDO SE PREPARA UN FÁRMACO DE COMBINACIÓN DE RANITIDINA, SUCRALFATO Y SUBCITRATO DE BISMUTO, ES POSIBLE HACER FRENTE A UN PROBLEMA DE HIGROSCOPICIDAD DE RANITIDINA Y AUMENTAR LA ESTABILIDAD DE LA FORMULACIÓN Y DISPONIBILIDAD BIOLÓGICA DE FÁRMACOS POR MEDIO DEL CONTROL DE LOS TAMAÑOS DE PARTÍCULA DE SUCRALFATO Y SUBCITRATO DE BISMUTO.</p><p> A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES THAT INCLUDES RANITIDINE, SUCRALPHATE AND BISMUTE SUBCITRATE AS ACTIVE COMPONENTS AND A METHOD OF PREPARATION OF THE SAME. IN ACCORDANCE WITH THE PRESENT INVENTION, WHEN PREPARING A RANITIDINE COMBINATION DRUG, SUCRALPHATE AND BISMUTE SUBCITRATE, IT IS POSSIBLE TO FACE A RANITIDINE HYGROSCOPICITY PROBLEM AND INCREASE THE STABILITY OF THE STABILITY OF THE DISABILITY OF THE STABILITY OF SUCRALPHATE PARTICLE SIZES AND BISMUTO SUBCITRATE. </p>

CL2017001680A 2015-01-30 2017-06-23 Pharmaceutical composition for the treatment of gastrointestinal diseases CL2017001680A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
CL2017001680A1 true CL2017001680A1 (en) 2018-01-12

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001680A CL2017001680A1 (en) 2015-01-30 2017-06-23 Pharmaceutical composition for the treatment of gastrointestinal diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX375765B (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
JP7585043B2 (en) * 2018-04-13 2024-11-18 サムヤン ホールディングス コーポレイション Pharmaceutical compositions containing lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
DE69525620T2 (en) * 1994-04-26 2002-10-17 Chugai Seiyaku K.K., Tokio/Tokyo METHOD FOR PRODUCING MEL-GRANULATED SUCRAL FATE PREPARATION
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
JP2001513570A (en) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー Combination preparation for treatment of upper gastrointestinal upset
AU4655199A (en) * 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
WO2010001930A1 (en) * 2008-07-01 2010-01-07 ライオン株式会社 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
AR105413A1 (en) 2017-10-04
CN107205947A (en) 2017-09-26
CN107205947B (en) 2020-05-22
EA032385B9 (en) 2019-07-31
PE20171340A1 (en) 2017-09-13
UA116517C2 (en) 2018-03-26
EP3250199A2 (en) 2017-12-06
MA41432A (en) 2017-12-05
MX2017007567A (en) 2017-10-19
KR101583452B1 (en) 2016-01-11
ECSP17038599A (en) 2017-09-29
BR112017013857A2 (en) 2018-02-27
JP6419347B2 (en) 2018-11-07
GEP20196941B (en) 2019-01-10
PH12017550051A1 (en) 2018-01-29
EA201791458A1 (en) 2017-11-30
TWI635859B (en) 2018-09-21
WO2016122226A2 (en) 2016-08-04
WO2016122226A3 (en) 2016-09-15
CO2017006222A2 (en) 2017-09-20
KR20160094268A (en) 2016-08-09
MY195824A (en) 2023-02-22
KR101583452B9 (en) 2022-05-02
EP3250199A4 (en) 2018-08-08
SA517382016B1 (en) 2021-03-18
EA032385B1 (en) 2019-05-31
JP2018503672A (en) 2018-02-08
TW201639559A (en) 2016-11-16
MX375765B (en) 2025-03-07

Similar Documents

Publication Publication Date Title
CL2020000501A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and their uses.
CL2018000684A1 (en) Modulators of hepatitis core protein b.
CL2018000223A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
MX2020004467A (en) METHODS FOR THE TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST.
DOP2016000233A (en) HEPATITIS B CORE PROTEIN ANOSTERIC MODULATORS
CL2018000706A1 (en) Derivatives of pyrazolopyrimidine as btk inhibitors for the treatment of cancer.
MX2016010854A (en) METHODS FOR THE TREATMENT OR PREVENTION OF ASTHMA THROUGH THE ADMINISTRATION OF AN IL-4R ANTAGONIST.
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
CR20170361A (en) DOSAGE FORM INCLUDING A SOLID SOLUTION OF AMORPH DRUGS
MX2015010312A (en) METHODS FOR TREATMENT OF MELANOMA.
ECSP17053843A (en) POWDERED NASAL FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
CL2017001483A1 (en) Fixed ratio formulation of insulin glargine / lixisenatide
CO2016003340A2 (en) Pharmaceutical formulations, processes for preparation and methods of use
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
CL2016002879A1 (en) Pharmaceutical compositions for treating infectious diseases
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
MX2017012596A (en) A pharmaceutical composition and the use thereof.
MX2016015261A (en) Allisartan isoproxil solid dispersion and pharmaceutical composition thereof.
PE20160596A1 (en) FORMULATION OF ATAZANAVIR AND COBICISTAT FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUSES
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.
BR112016028083A2 (en) ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN AND ITS PREPARATION PROCESS
CL2017001680A1 (en) Pharmaceutical composition for the treatment of gastrointestinal diseases
MX2016005227A (en) Long-acting polypeptides and methods of producing and administering same.
MX2017013633A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES.